The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B‐ ALL With High Disease Burden

医学 Blinatumoab公司 内科学 耐火材料(行星科学) 肿瘤科 队列 人口 疾病 回顾性队列研究 外科 细胞因子释放综合征 队列研究 免疫疗法 白血病 急性淋巴细胞白血病 总体生存率 挽救疗法 化疗 疾病负担 存活率 骨髓 淋巴细胞白血病
作者
Jose Tinajero,Kim Ngoc Nguyen,Dat Ngo,Vaibhav Agrawal,Haoyue Shan,Jianying Zhang,Paul Koller,Hoda Pourhassan,Lindsey A. Murphy,Yazeed Samara,Shukaib Arslan,Stephen J. Forman,Anthony Selwyn Stein,Guido Marcucci,Vinod A. Pullarkat,Ibrahim Taha Aldoss
出处
期刊:American Journal of Hematology [Wiley]
卷期号:100 (12): 2209-2219 被引量:3
标识
DOI:10.1002/ajh.70057
摘要

Blinatumomab is approved for the treatment of relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Studies have correlated pre-blinatumomab high disease burden (HDB) [> 50% bone marrow blasts (BMB)] with lower response rates and increased risk for toxicities, including cytokine release syndrome (CRS) and neurotoxicity (NT). While the administration of pre-blinatumomab cytoreductive therapy is an appealing approach, larger studies validating the beneficial effect of this strategy in patients with HDB are lacking. We retrospectively analyzed 148 adult patients with R/R B-ALL treated with blinatumomab. Patients were grouped as low disease burden (LDB, n = 55), HDB without cytoreduction (n = 41), and HDB with cytoreduction (n = 52). The median age for the cohort was 40 years; the majority were males (63%) and Hispanic (73%), and the most common ALL subtype was Ph-like (40%). Patients with HDB with cytoreduction had a significantly higher rate of prior alloHCT (p = 0.041) and more lines of prior therapy (p = 0.006) compared to the other cohorts. Compared to patients with HDB, those with LDB had significantly higher response rates to blinatumomab (p < 0.0001), while rates of CRS and NT were not significantly different. Among patients with HDB, cytoreductive therapy was associated with a significantly lower rate of CRS compared to those who did not receive cytoreduction (p = 0.038). However, cytoreduction had no significant impact on treatment response, MRD negativity, or NT. Patients with B-ALL and HDB remain a challenging population for blinatumomab therapy; while cytoreduction may improve safety by reducing CRS, novel strategies are needed to enhance treatment efficacy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
斑马完成签到,获得积分10
刚刚
111发布了新的文献求助10
1秒前
英俊的铭的应助被王诗琪采纳,获得10
2秒前
2秒前
燚槿发布了新的文献求助10
3秒前
4秒前
4秒前
等璃子完成签到,获得积分10
4秒前
業業完成签到,获得积分10
5秒前
乌龙茶发布了新的文献求助10
5秒前
7秒前
WhiteSand完成签到,获得积分10
7秒前
8秒前
ding的应助被111采纳,获得10
8秒前
水煮电吹风的应助被杨波采纳,获得10
9秒前
9秒前
10秒前
舒服的滑板完成签到 ,获得积分10
10秒前
10秒前
温暖煎饼完成签到,获得积分10
11秒前
11秒前
年轻小之发布了新的文献求助10
11秒前
cenjin完成签到 ,获得积分10
12秒前
12秒前
13秒前
FG发布了新的文献求助10
13秒前
buxiaode512完成签到,获得积分10
13秒前
xiaoxu发布了新的文献求助30
13秒前
13秒前
NuyGinX完成签到,获得积分10
14秒前
mmmc完成签到,获得积分10
15秒前
15秒前
cc2004bj发布了新的文献求助50
15秒前
薛广苏完成签到,获得积分10
16秒前
16秒前
火星上的大炮完成签到,获得积分10
16秒前
16秒前
踏实的问凝完成签到,获得积分10
17秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568